RGP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RGP is not a good buy right now for an impatient investor. The trend is still bearish (SMA200>SMA20>SMA5 with negative MACD), and the latest quarter (2026/Q2) shows sharp YoY deterioration in revenue and profitability. Insider buying is a notable positive, but it is not enough to override the weak trend and weak fundamentals without a proprietary buy signal or a clear catalyst.
Price/Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), signaling an ongoing downtrend. Momentum: MACD histogram -0.029 (below zero) but negatively contracting, implying downside momentum is weakening (possible early stabilization), not yet a reversal. RSI: RSI_6 = 37.47 (near oversold but still technically neutral), suggesting limited immediate downside may remain but no confirmed bounce signal. Key levels: Pivot 4.433 (current ~4.465 just above pivot). Near-term resistance R1 4.636 then R2 4.761; supports S1 4.231 then S2 4.106. A break below ~4.23 would reinforce downside continuation. Pattern-based near-term expectation: Similar-pattern stats imply small upside next day/week (+0.46% / +1.38%) but slightly negative next month (-0.27%), consistent with weak medium-term trend.
Intellectia Proprietary Trading Signals
Insider activity is strongly positive: insiders are buying, with buying amount up ~800% over the last month.
Downside momentum is weakening (MACD histogram contracting), which can precede a technical bounce if price holds above ~4.23–4.10 support.
Options open interest skews bullish (very low put/call OI), though volume is minimal.
Fundamentals are deteriorating: 2026/Q2 revenue -19.15% YoY and net income/EPS deeply negative (net income -$12.66M; EPS -0.38), with gross margin also down.
Technical trend remains bearish (MA stack-down) with MACD still below zero.
No news catalysts in the past week to change narrative or drive re-rating.
Hedge funds are neutral with no significant trend over the last quarter (no strong institutional tailwind indicated).
Latest quarter: 2026/Q2. Revenue: $117.732M, down 19.15% YoY (clear contraction). Profitability: Net income -$12.661M (down 81.57% YoY) and EPS -0.38 (down 81.73% YoY), indicating worsening losses. Margins: Gross margin 35.86%, down 3.39% YoY, showing pressure on operating quality. Overall: Negative growth and worsening profitability do not support an aggressive buy-now decision.
No analyst rating/price target change data was provided, so a recent Wall Street trend assessment cannot be confirmed here. Based on the available data only, the main 'pro' case would be insider buying and potential mean-reversion from a weakened momentum state; the main 'con' case is the clear downtrend plus materially weakening YoY financial performance. Politician/congress activity: no recent congress trading data available.
